184 related articles for article (PubMed ID: 34355385)
1. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
[No Abstract] [Full Text] [Related]
2. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
3. Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial.
Kang JM; Park KH; Ahn S; Cho S; Han A; Lee T; Jung IM; Kim JY; Min SK
Sci Rep; 2019 Dec; 9(1):20356. PubMed ID: 31889152
[TBL] [Abstract][Full Text] [Related]
4. Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban.
Rokos J; Heger M; Stöllberger C; Finsterer J; Laufer G; Wiedemann D
Int J Cardiol; 2016 Oct; 221():383-4. PubMed ID: 27404710
[No Abstract] [Full Text] [Related]
5. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
6. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
[No Abstract] [Full Text] [Related]
7. Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.
Platton S; Bowles L; MacCallum P
Br J Haematol; 2017 Nov; 179(3):511-513. PubMed ID: 27392166
[No Abstract] [Full Text] [Related]
8. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Oral Xa Inhibitor for Management of Ischemic Stroke Associated with Thrombosis in the Pulmonary Vein Stump after Lung Resection.
Amemiya T; Shono T; Yamagami K; Takagishi S; Toma H; Kobarai T; Eguchi T; Hirota I
J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104321. PubMed ID: 31422005
[TBL] [Abstract][Full Text] [Related]
10. Use of Rivaroxaban for Mesenteric Vein Thrombosis Secondary to Diverticulitis: A Case Report.
Parthvi R; Mehra S
Am J Ther; 2017; 24(5):e629-e630. PubMed ID: 27759584
[No Abstract] [Full Text] [Related]
11. Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: A case report.
Kido K; Noyes E; Gutnik L
J Clin Pharm Ther; 2017 Oct; 42(5):631-633. PubMed ID: 28497637
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
Langenbruch L; Meuth SG; Wiendl H; Mesters R; Möddel G
Seizure; 2020 Aug; 80():46-47. PubMed ID: 32521502
[No Abstract] [Full Text] [Related]
14. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
[TBL] [Abstract][Full Text] [Related]
15. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
[TBL] [Abstract][Full Text] [Related]
16. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
18. A Case Report of Henoch-Schonlein Purpura and IgA Nephropathy Associated With Rivaroxaban.
Chung EY; Chen J; Roxburgh S
Nephrology (Carlton); 2018 Mar; 23(3):289-290. PubMed ID: 29461002
[No Abstract] [Full Text] [Related]
19. Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report.
Zhou H; Wei Q; Wu H; Tang M; Yang S; Liu Y; Qin L
Medicine (Baltimore); 2019 May; 98(20):e15705. PubMed ID: 31096518
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
